Demuris

Demuris is a UK private antibiotic discovery biotechnology company focused on natural product-derived anti-infectives. Originating as a Newcastle University spinout, the company applies genome engineering, natural product sourcing, biosynthetic gene cluster activation, and target-based screening to discover and optimize new small-molecule antibiotics. Its disclosed pipeline includes anti-tuberculosis and broader antimicrobial-resistance programs, including kanglemycin A-related rifamycin chemistry and a discovery-stage RNA polymerase inhibitor program. Demuris appears to operate primarily as an early-stage R&D and partnering company, aiming to generate intellectual property and out-license programs rather than commercialize products directly. The company remains legally active, although public information suggests a very small operating footprint and limited recent disclosure of a broad internal pipeline.